Literature DB >> 17077331

4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4.

Suk Hang Cheng1, Margaret H L Ng, Kin Mang Lau, Herman S Y Liu, Joyce C W Chan, Angela B Y Hui, Kwok Wai Lo, Hua Jiang, Jian Hou, Raymond W Chu, Wai Shan Wong, Natalie P H Chan, Ho Keung Ng.   

Abstract

In this study, we have elucidated the chromosomal imbalances in the multistep pathogenesis and delineated several critical tumor suppressor gene (TSG) loci in multiple myeloma (MM). By using comparative genomic hybridization, allelotyping, and multicolor interphase fluorescence in situ hybridization, 5 MM cell lines and bone marrow CD138+ plasma cells from 88 Chinese patients with monoclonal gammopathy of undetermined significance (MGUS) and early and advanced stages of MM were investigated. In all MGUS and MM samples, chromosome copy number abnormalities were detected. A higher number of chromosomal imbalances and specific genetic alterations are involved in MGUS to MM transition (-6q, +3p, and +1p) and MM progression (+2p and +9q). In addition to -13q, we first found high frequencies (42% to 46%) of -4q involving high percentages (70% to 74%) of clonal plasma cells in both MGUS and MM, suggesting that inactivation of TSG in this region is also a potentially critical genetic event in MM tumorigenesis. By high-resolution allelotyping, we defined a common deletion region on 4q13.3 and found that a candidate TSG, platelet factor 4, was frequently silenced by promoter hypermethylation in MM (15 of 28) and MM cell lines (5 of 5). These data have opened up a new approach in the molecular targeting therapy and provide novel insights into MM tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077331     DOI: 10.1182/blood-2006-04-018770

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Platelet factor 4 increases bone marrow B cell development and differentiation.

Authors:  David J Field; Angela A Aggrey-Amable; Sara K Blick; Sara K Ture; Andrew Johanson; Scott J Cameron; Sukanya Roy; Craig N Morrell
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

2.  Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells.

Authors:  Soumya V Nair; Małgorzata A Witek; Joshua M Jackson; Maria A M Lindell; Sally A Hunsucker; Travis Sapp; Caroline E Perry; Mateusz L Hupert; Victoria Bae-Jump; Paola A Gehrig; Weiya Z Wysham; Paul M Armistead; Peter Voorhees; Steven A Soper
Journal:  Chem Commun (Camb)       Date:  2015-02-21       Impact factor: 6.222

3.  A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer.

Authors:  Hossein Hozhabri; Marziyeh Mazaheri Moghaddam; Madiheh Mazaheri Moghaddam; Ali Mohammadian
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

4.  Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma.

Authors:  Pei Liang; Suk Hang Cheng; Chi Keung Cheng; Kin Mang Lau; Shek Ying Lin; Eudora Y D Chow; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Margaret H L Ng
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

5.  RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma.

Authors:  Ying-Ying Liang; Li-Sheng Zheng; Yuan-Zhong Wu; Li-Xia Peng; Yun Cao; Xue Cao; Ping Xie; Bi-Jun Huang; Chao-Nan Qian
Journal:  Cell Cycle       Date:  2014-03-10       Impact factor: 4.534

6.  Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.

Authors:  Xiaotong Chen; Shengjin Fan; Yanqiu Zhao; Jin Zhou
Journal:  Clin Transl Oncol       Date:  2021-05-03       Impact factor: 3.405

7.  Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo.

Authors:  Longjiang Yang; Juan Du; Jian Hou; Hua Jiang; Jianfeng Zou
Journal:  BMC Cancer       Date:  2011-06-21       Impact factor: 4.430

8.  CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells.

Authors:  Fumiya Ohashi; Shigeru Miyagawa; Satoshi Yasuda; Takumi Miura; Takuya Kuroda; Masayoshi Itoh; Hideya Kawaji; Emiko Ito; Shohei Yoshida; Atsuhiro Saito; Tadashi Sameshima; Jun Kawai; Yoshiki Sawa; Yoji Sato
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

9.  Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma.

Authors:  Ju Bai; Yun Yang; Jianli Wang; Lei Zhang; Fangxia Wang; Aili He
Journal:  Clin Proteomics       Date:  2019-04-23       Impact factor: 3.988

10.  Association of mammographic density with blood DNA methylation.

Authors:  Rachel M Lucia; Wei-Lin Huang; Andrea Alvarez; Irene Masunaka; Argyrios Ziogas; Deborah Goodman; Andrew O Odegaard; Trina M Norden-Krichmar; Hannah Lui Park
Journal:  Epigenetics       Date:  2021-06-11       Impact factor: 4.861

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.